{
    "root": "9c80624b-cef2-43ae-b676-a73f414b6683",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cyclobenzaprine Hydrochloride",
    "value": "20250312",
    "ingredients": [
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "cyclobenzaprine hydrochloride tablets , usp indicated adjunct rest physical therapy relief muscle spasm associated acute , painful musculoskeletal conditions . improvement manifested relief muscle spasm associated signs symptoms , namely , pain , tenderness , limitation motion , restriction activities daily living . cyclobenzaprine hydrochloride tablets , usp used short periods ( two three weeks ) adequate evidence effectiveness prolonged available muscle spasm associated acute , painful musculoskeletal conditions generally short duration therapy longer periods seldom warranted . cyclobenzaprine hydrochloride tablets , usp found effective treatment spasticity associated cerebral spinal cord disease , children cerebral palsy .",
    "contraindications": "patients , recommended dose cyclobenzaprine hydrochloride tablets 5 mg three times day . based individual patient response , dose may increased 10 mg three times day . cyclobenzaprine hydrochloride tablets periods longer two three weeks recommended . ( usage ) . less frequent dosing considered hepatically impaired elderly patients ( , impaired hepatic function , elderly ) .",
    "warningsAndPrecautions": "cyclobenzaprine hydrochloride tablets usp , 10 mg butterscotch yellow , biconvex , 5-sided d-shaped film-coated tablets , debossed \u2018 \u2019 \u2018 32 \u2019 one side plain side . bottles 15 ndc 68788-8167-5 bottles 20 ndc 68788-8167-2 bottles 30 ndc 68788-8167-3 bottles 60 ndc 68788-8167-6 bottles 90 ndc 68788-8167-9 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . distributed : rising pharma holdings , inc. east brunswick , nj 08816 made india code : ts/drugs/19/1993 issued : 05/2021 repackaged : preferred pharmaceuticals inc .",
    "adverseReactions": "hypersensitivity component product . concomitant monoamine oxidase ( mao ) inhibitors within 14 days discontinuation . hyperpyretic crisis seizures , deaths occurred patients receiving cyclobenzaprine ( structurally similar tricyclic antidepressants ) concomitantly mao inhibitor drugs . acute recovery phase myocardial infarction , patients arrhythmias , heart block conduction disturbances , congestive heart failure . hyperthyroidism .",
    "indications_original": "Cyclobenzaprine hydrochloride tablets, USP\u00a0are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.\n                     Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.\n                     \n                     Cyclobenzaprine hydrochloride tablets, USP\u00a0should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.\n                     \n                      Cyclobenzaprine hydrochloride tablets, USP\u00a0have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications_original": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets\u00a0is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day.\u00a0 Use of cyclobenzaprine hydrochloride tablets for periods longer than two or three weeks\u00a0is not recommended. (see \n                        INDICATIONS AND USAGE\n                     ).\n                     Less frequent dosing should be considered for hepatically impaired or elderly patients (see \n                        PRECAUTIONS, Impaired Hepatic Function, and \n                        Use in the Elderly\n                     ).",
    "warningsAndPrecautions_original": "Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are butterscotch yellow, biconvex, 5-sided D-shaped film-coated tablets, debossed with \u2018D\u2019 and \u201832\u2019 on one side and plain on other side. \n                     \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 15\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 68788-8167-5\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 20\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8167-2\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8167-3\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 60\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8167-6\n                  \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 90\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 68788-8167-9\n                     \n                      STORAGE\n                     \n                     \n                      Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature]. \n                     \n                     Distributed\u00a0by:\n                     Rising Pharma Holdings, Inc. East Brunswick, NJ 08816\n                     \n                      Made in India\n                     \n                      Code: TS/DRUGS/19/1993\n                      Issued: 05/2021\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions_original": "Hypersensitivity to any component of this product.\n                     Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.\n                     Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.\n                     Hyperthyroidism."
}